The clinical impact of HIV in developed countries has been markedly reduced through the use of combination antiretroviral drug therapy. But strains of HIV resistant to some or all of these drugs have evolved and are spreading. How fast will they grow? (pages 1016–1020)
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Blower, S. et al. Predicting the unpredictable: The transmission of drug-resistant HIV. Nature Med. 7, 1016–1020 (2001).
Hecht, F.M. et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N. Engl. J. Med. 339, 307–311 (1998).
Yerly, S. et al. Transmission of antiretroviral drug resistant HIV1 variants. Lancet 354, 729–733 (1999).
UK Collaborative Group on Monitoring the transmission of HIV drug resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the UK. Brit. Med. J. 322, 1087–1088 (2001).
Little, S.J. et al. Antiretroviral drug susceptibility and response to initial therapy among recently HIV-infected subjects in North America. 8th Conference on Retroviruses and Opportunistic Infections, Chicago (4–8 February 2001).
Leigh Brown, A.J. et al. Transmission fitness of drug-resistant virus and the prevalence of resistance in the treated population. Abstract 145. Antivir. Ther. 6, 112 (2001).
Miller, V. et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14, 2857–2867 (2000).
Argentina NTTC on behalf of the Esprit International Team. Preliminary results of Esprit: Predictors of dosage reduction or cycle interruption during the first three cycles of IL-2. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires (8–11 July 2001).
Youle, M. et al. Randomised study of intermittent subcutaneous interleukin-2 (IL-2) therapy: Without antiretovirals versus no treatment. Abstract LBOr028. 13th International Conference on AIDS, Durban (July 2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Phillips, A. Will the drugs still work? Transmission of resistant HIV. Nat Med 7, 993–994 (2001). https://doi.org/10.1038/nm0901-993
Issue Date:
DOI: https://doi.org/10.1038/nm0901-993